[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@futuregateX FutureGate X

FutureGate X posts on X about $laes, $17520m, $cour, ai the most. They currently have XXX followers and X posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

• X Week XXXXXXX -XX%
• X Month XXXXXXXXX +30,550%
• X Months XXXXXXXXX +1,762%
• X Year XXXXXXXXX +52,351%

Mentions: X #

• X Week X -XX%
• X Month XX -XX%
• X Months XXX -XXXX%
• X Year XXX +1,560%

Followers: XXX #

• X Week XXX +1.70%
• X Month XXX +7.10%
• X Months XXX +43%
• X Year XXX +1,754%

CreatorRank: undefined #

Social Influence

Social category influence stocks XXXX% technology brands XXXX%

Social topic influence $laes 12.5%, $17520m 12.5%, $cour 12.5%, ai 12.5%, in 2026 12.5%, $amd 12.5%, $citi 12.5%, $vrt 12.5%, $asx 12.5%, $ptx XXXX%

Top accounts mentioned or mentioned by @drmanhattanasx @dr_manhattanasx

Top assets mentioned Coursera, Inc. (COUR) Advanced Micro Devices (AMD) Vertiv Holdings Co (VRT) ASE Technology Holding Co., Ltd. (ASX)

Top Social Posts

Top posts by engagements in the last XX hours

"💡 Tech Update 📊 $LAES reaffirms FY25 revenue ($17.520M) sees 50100% growth in 2026 🎓 $COUR partners with #Anthropic on new AI training tracks $AMD chips to power Frances first supercomputer-dubbed king of the hill in chips $Citi ⚡ $VRT and #Caterpillar partner on #AIdatacentre energy systems 🔥 #JeffBezos returns to co-lead Project #Prometheus (AI for engineering & #aerospace) 🏦 $BofA says AI is boosting banker productivity & revenue 🤝 #Saudis #Humain set to announce tech deals with $AMZN & $AMD 💸 #Anthropic valued at $350B after #Microsoft & $NVDA deal 🖥 $SMCI showcases new AI & HPC"
X Link 2025-11-18T23:31Z XXX followers, XXX engagements

"Our 2026 $ASX high-conviction pick- $PTX 🥇🚀 The biotech sector is emerging from its deepest bear market in decades and small caps have just printed new record highs a strong backdrop for re-rating opportunities. PTX sits at the centre of this recovery with a pivotal Phase X readout ahead. Management looks highly confident: if the company replicates its Phase X data XXX% clinical benefit zero safety issues the program will most likely advance into a Phase 2b registrational trial. The addressable market is meaningful. CTCL has no effective therapies today and PTX holds Orphan Drug Designation"
X Link 2025-12-09T23:46Z XXX followers, XX engagements

"@Dr_ManhattanASX Agreed also a great catalyst for sector tailwind"
X Link 2025-12-10T03:24Z XXX followers, XX engagements